Jeff Yass’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History

Jeff Yass’s Portfolio NBRV Stock Details NBRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-608	Closed	-$6K	–	14619
2022 Q1	$6K	Sell	608 -664	-52%	-$8.07K	﹤0.01%	12813
2021 Q4	$19K	Sell	1,272 -640	-33%	-$15.2K	﹤0.01%	12841
2021 Q3	$57K	Sell	1,912 -1,412	-42%	-$39.9K	﹤0.01%	12311
2021 Q2	$112K	Sell	3,324 -3,568	-52%	-$133K	﹤0.01%	12038
2021 Q1	$286K	Buy	6,892 +4,520	+191%	+$281K	﹤0.01%	10714
2020 Q4	$144K	Buy	2,372 +2,231	+1,582%	+$242K	﹤0.01%	10275
2020 Q3	$19K	Buy	+141	New	+$23.6K	﹤0.01%	10382
2020 Q2	–	Sell	-51	Closed	-$7K	–	11370
2020 Q1	$7K	Sell	51 -56	-52%	-$17.1K	﹤0.01%	10086
2019 Q4	$35K	Sell	107 -64	-37%	-$29.4K	﹤0.01%	9417
2019 Q3	$86K	Sell	171 -5	-3%	-$2.82K	﹤0.01%	9628
2019 Q2	$107K	Buy	+176	New	+$108K	﹤0.01%	9576
2018 Q4	–	Sell	-153	Closed	-$103K	–	10404
2018 Q3	$103K	Buy	153 +51	+50%	+$36.1K	﹤0.01%	8599
2018 Q2	$89K	Buy	102 +20	+24%	+$22.9K	﹤0.01%	9085
2018 Q1	$103K	Buy	+82	New	+$121K	﹤0.01%	8692

Other funds holding NBRV

VFA

Values First Advisors Gray, Tennessee $219M AUM 33.32% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Jeff Yass's NBRV Position: Q1 2023 in Review

Jeff Yass sold out of Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q1 2023, closing a stake of 22,294 shares — an estimated $41K sold.

Jeff Yass first reported a position in NBRV in Q4 2017 and held it in 17 quarters. The position peaked at $1.11M in Q2 2019. 12 funds tracked by Wall St. Rank hold NBRV as of Q1 2023.

Jeff Yass reported no remaining Nabriva Therapeutics plc Ordinary Shares Ireland position as of Q1 2023 after selling out during the quarter.
Jeff Yass sold 22,294 Nabriva Therapeutics plc Ordinary Shares Ireland shares in Q1 2023, an estimated $41K.
Jeff Yass first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q4 2017 and held it in 17 quarters.
Jeff Yass's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $1.11M in Q2 2019.
12 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q1 2023.

Based on Susquehanna International Group's 13F filing for Q1 2023, filed 16 May 2023.